Abstract: Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Abstract: Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Abstract: The invention relates to novel aminopyridine derivatives of formula (I) wherein R1 is methyl an R4 and amino group —NR6R7 and R5 forms an arylalkynyl- or heteroarylalkynyl-group. The compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

Abstract: The present invention relates to new tetrazole compounds of formula I wherein B, P, Q, W, R1 and R2 are defined in the description: invention compounds are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) X R1 N Y (I) R2 R3 wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

Abstract: The invention relates to novel aminopyridine derivatives of formula (I) wherein R1 is methyl an R4 and amino group —NR6R7 and R5 forms an arylalkynyl- or heteroarylalkynyl-group.

Abstract: An operating table including at least three elements which are moveable in relation to each other; at least two actuators, each controlling displacement of two elements in relation to the other; a controller which drives each actuator; a sensor to detect a risk of collision of one of the elements with an obstacle when executing a displacement request of a first actuator; a controller which determines a corrective command order of a second actuator different from the first actuator upon detecting a risk of collision, wherein execution of the corrective command order by the second actuator causes cessation of the detected risk of collision upon subsequent execution of the displacement request of the first actuator; and a display to view the corrective command order.

Abstract: An operating table including at least three elements which are moveable in relation to each other; at least two actuators, each controlling displacement of two elements in relation to the other; a controller which drives each actuator; a sensor to detect a risk of collision of one of the elements with an obstacle when executing a displacement request of a first actuator; a controller which determines a corrective command order of a second actuator different from the first actuator upon detecting a risk of collision, wherein execution of the corrective command order by the second actuator causes cessation of the detected risk of collision upon subsequent execution of the displacement request of the first actuator; and a display to view the corrective command order.

Abstract: The invention relates to novel aminopyridine derivatives of formula (I) wherein R1 is methyl an R4 and amino group —NR6R7 and R5 forms an arylalkynyl- or heteroarylalkynyl-group. The compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

Abstract: Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Abstract: A process is described that can limit pressure drops during a catalytic hydrotreatment process carried out in a fixed bed reactor. The liquid feed and gaseous reactant are injected into the reactor either side of the bed and flow as a counter-current. Pressure drops are limited by homogeneously mixing solid catalytic and/or inert particles of different diameters in the bed.

Abstract: The control system comprises a microphone (7) linked to a receiver block (9) and delivering audio signals to a discriminating block (11) comparing the voice profile of the speaker with a particular authorized speaker profile recorded in a personal chip card (20) of the speaker. The authorized audio signals are then processed in a voice recognition device and an electronic control unit so as to selectively activate one of the actuators (3) of the operating table in response to a specific voice command uttered into the microphone and effected by an effector (16) actuated by the speaker.

Abstract: A process is described that can limit pressure drops during a catalytic hydrotreatment process carried out in a fixed bed reactor. The liquid feed and gaseous reactant are injected into the reactor either side of the bed and flow as a counter-current. Pressure drops are limited by homogeneously mixing solid catalytic and/or inert particles of different diameters in the bed.

Abstract: Bi-aromatic compounds are provided along with methods for their preparation and use.

Abstract: A part is made of a composite material having an alumina matrix by impregnating a fiber texture with a fluid composition containing a liquid precursor of alumina, a thermoplastic resin, and a suspension of alumina powder, and subsequently convening the precursor into alumina. Additional solid fillers may be added to the impregnation composition. The impregnated fiber texture is preferably made by draping and molding plies that are pre-impregnated with said composition.

Abstract: In a process according to the invention, before a carbon/fiber ceramic matrix is densified, the carbon fiber reinforcement material is subjected to a thermal treatment in a non-oxidizing environment at a temperature greater than 1300.degree. C. and less than 2200.degree. C., to act on the bonding between the fibers and the matrix. If a preform of the carbon fiber reinforcement material is formed prior to densification by a matrix, then the thermal treatment may be performed on the preform, prior to densification by the matrix. If the matrix is densified by chemical vapor infiltration inside a furnace, then the thermal treatment may be performed inside the infiltration furnace prior to the densification. The thermal treatment achieves a significant improvement in the strength of the resulting composite material.

Abstract: Benzimidazole derivatives having general formula (I), wherein R.sub.1 and R.sub.2 are a hydrogen atom, a lower alkyl radical, an OR.sub.4 radical, a lower fluoroalkyl radical or a halogen atom; R.sub.3 is a hydrogen atom, a lower alkyl radical, a halogen, a hydroxyl or a lower alkoxy radical having 1-6 carbon atoms; R.sub.4 is a hydrogen atom, a lower alkyl radical, a benzyl radical or a (II) radical, PO.sub.3 H, SO.sub.3 H or an aminoacid residue; R.sub.7 is a lower alkyl radical, a lower alkoxy radical having 1-6 carbon atoms, a --(CH.sub.2).sub.n --COOH radical where n=1-6, or the radical (III), where r' and r" are a hydrogen atom or a lower alkyl radical, or form, together with the nitrogen atom, a 5 or 6-membered heterocyclic ring optionally interrupted by a heteroatom; R.sub.5 and R.sub.6 are different and represent the OR.sub.8 radical or a mono or polycyclic cycloalkyl radical having 5-12 carbon atoms bound to the phenyl core by a tertiary carbon; R.sub.

Abstract: The thermostructural composite material is produced by forming a fibrous preform made from refractory fibers coated with a sizing agent. The preform is densified by a refractory matrix, in particular ceramic, while a carbon interphase is provided between the fibers and the matrix. The fibrous preform is made from refractory fibers coated with a sizing agent of the type that leaves behind a carbon residue upon thermal decomposition. The carbon interphase is produced by the thermal degradation of the sizing agent, occurring for example after the preform is made. The sizing agent is chosen among phenolic, acrylic and cellulose resins, and in particular carboxymethylcellulose.

Abstract: A composition is provided which is coextrudable with vinylidene polyfluoride permitting it to adhere to incompatible polymeric resins, the composition which has a base of an alkyl polymethacrylate and a thermoplastic polymer is comprised of:from 27 to 50 parts by weight of an alkyl polymethacrylate; andfrom 73 to 50 parts by weight of an additive itself constituted for 100 portions by weight of additive of:from 35 to 50 parts by weight of PVDF, andfrom 65 to 50 parts by weight of acrylic or methacrylic elastomer.This composition serves to produce vinylidene polyfluoride compounds capable of coating polymers which are non-compatible with vinylidene polyfluoride. When used as an adhesion agent, one can obtain by coextrusion, compounds of vinylidene polyfluoride and polymers non-compatible with the vinylidene polyfluoride.